503B Compounding Pharmacy

Implementing these standards can be logistically challenging.

The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.

An increased demand for methylphenidate products as a result of Adderall shortages has led to a short supply of some popular products, including Ritalin and Concerta.

For many patients with C diff, the experience of medical gaslighting is a common one because many health care providers lack education and familiarity with the disease.

Drug shortages have led to increased use of compounding pharmacy.

Analyzing the patent and trademark challenges faced by 503A compounding pharmacies.

When considering outsourcing, pharmacies should use a multistakeholder team to weigh pros and cons.

Illegal online sellers threaten the health, privacy, and security of patients by failing to comply with the laws of the jurisdiction in which they are located, or the jurisdiction in which they are selling their medicines.

Pharmacists will play a growing role in the use of biosimilars and guiding patients through the switching process.

The FDA’s temporary Guidance for 503A compounding of shortage drugs was meant to be temporary and withdrawn once COVID-19 ended.

Part 1 of this 2-part series examines USP <797> and <795> revisions for sterile and nonsterile compounding, veterinary compounding, FDA inspections of 503A pharmacies, and the interstate distribution of compounded prescriptions post Wellness Pharmacy v. FDA.

This action is of considerable significance as it supports the regulation of cannabis and cannabis-derived products as medicine under the Federal Food, Drug and Cosmetic Act.

As of November 2022, amoxicillin suspension has been on a national shortage list, therefore the FDA has permitted temporary compounding of amoxicillin suspensions.

Psilocybin is derived from certain types of mushrooms and has been proven to affect serotonin receptors.

Complete due diligence before selecting a compounding pharmacy and establishing an outsourcing relationship.

Technology gains traction in health-system pharmacies for drug inventory and to automate applications.

One day soon, including pharmacogenomics testing for all patients will be essential for precise prescribing.

Pharmacists are the premier medication experts within health care, who understand more about medication interactions than most physicians and have the unique ability to prevent complications, improve adherence, and save lives.

A more comprehensive body of regulations is required to achieve consistency and safety for patients.

Farah Towfic, PharmD, MBA, RPh, director, CEO Operations, US Pharmacopeia, details some of the moments that led her to the pharmacy field and the important role that mentorship played in that process.

With a trained representative focused on building relationships with prescribers in the community, pharmacies have the opportunity to significantly expand how they do business.

The value proposition for point-of-care testing in the pharmacy is extensive, as pharmacies can provide a convenient, accessible, and cost-saving alternative for patients.

Key questions to ask when deciding whether compounding facilities are the right fit.

Pharmacists should get involved in all the various aspects of their business and with the different professional groups available.

Research indicates that poor technique or failure to follow up-to-date standards and protocols could lead to injury or even death of patients who need compounded medications.

Prescribers signed a letter expressing concerns about recommendations for restrictions on compounded hormones, which millions of women and other patient populations rely on.

Desmond Hunt, PhD, senior principal scientist at US Pharmacopeia (USP), discusses the standards and resources that USP has recently published or is looking at now on the subject of pharmacy in transit.

FDA regulations under Food, Drug, and Cosmetic Act outline efficacy, safety requirements for animal pharmaceuticals.

Although innovation in the pharmacy space is continuing nearly 3 years into the COVID-19 pandemic, provider status and reimbursement are both necessary to continue this innovation in the future.

Following the seemingly endless disruptions to the country’s supply chain over the past 2-year period, signs are showing more pain before things get better.